Key Takeaways
- Clinical Bottom Line
- Do not drain the scan. Drain the problem.
- Timing still matters, but timing is not a cartoon rule
- Where EUS-guided drainage is strongest in 2026
Clinical Bottom Line
| PFC scenario | 2026 practical answer |
|---|---|
| Asymptomatic pseudocyst or walled-off necrosis | Do not drain it just because it is large. Current practice still treats symptoms, infection, obstruction, and nutritional failure, not CT anxiety. |
| Stable infected or symptomatic WON adherent to the stomach or duodenum in an expert center | EUS-guided transmural drainage is a strong first-line option and is often preferred over surgery when anatomy is favorable. |
| Acute necrotic collection in the first 2 weeks, very ill patient, or deep paracolic or pelvic extension | Percutaneous drainage still matters. Endoscopy did not replace interventional radiology in these scenarios. |
| Necrotic collection likely to need repeated endoscopic access | LAMS are useful, especially when direct endoscopic necrosectomy may be needed, but they are not a mandatory device for every drained collection. |
| Drainage alone is not enough | Reserve direct endoscopic necrosectomy for collections that do not improve adequately after drainage, and do it where radiology and surgical backup exist. |
Do not drain the scan. Drain the problem.
Peripancreatic fluid collection is not a synonym for intervention. Busy endoscopists still need the same first question that mattered before LAMS became ubiquitous: is this collection infected, painful, obstructing, driving nutritional failure, or keeping the patient systemically unwell?
That question still anchors current guidance. AGA’s pancreatic necrosis update remains clinically useful here. Drainage or debridement is indicated for infected necrosis and may also be needed for otherwise sterile necrosis when abdominal pain, nausea, vomiting, nutritional failure, luminal or biliary obstruction, recurrent pancreatitis, fistulas, or persistent SIRS make observation inadequate.
Timing still matters, but timing is not a cartoon rule
The timing conversation often gets flattened into “wait 4 weeks no matter what” or “drain early because the patient looks bad.” Current practice is more nuanced.
For stable pancreatic necrosis, both AGA and the 2024 ACG guideline still support delaying intervention until the collection is organized, often around 4 to 6 weeks. That improves safety and makes debridement more effective. But that principle is not the same thing as blind waiting. Percutaneous drainage remains appropriate early, especially within the first 2 weeks, in patients who are too ill for endoscopic or surgical intervention or when necrosis tracks deeply into the paracolic gutters or pelvis.
The 2025 TIMING trial is helpful because it pushes back against the reflex to intervene early just because the patient is very sick. In patients with acute necrotic collections and early persistent organ failure, early catheter drainage did not improve clinical outcomes compared with standard delayed care.
Where EUS-guided drainage is strongest in 2026
When a symptomatic or infected pseudocyst or walled-off necrosis is closely apposed to the stomach or duodenum and experienced therapeutic EUS support is available, EUS-guided transmural drainage is often the cleanest first move. For WON, AGA still treats endoscopic transmural drainage and percutaneous drainage as appropriate first-line nonsurgical approaches, with endoscopic therapy often preferred when anatomy is favorable because it avoids an external fistula.
That matters for workflow. A good transmural drainage plan can relieve sepsis, improve intake, and set up later necrosectomy only if it is actually needed. Not every collection needs a procedure marathon on day 1.
Percutaneous drainage still belongs in the modern algorithm
The availability of LAMS has made some discussions sound as though interventional radiology is the historical fallback. That is not how current guidance reads. Percutaneous drainage is still a first-line tool in selected early infected collections, in patients who are too unstable for transluminal work, and as an adjunct when the cavity extends beyond what a transgastric or transduodenal route can treat well.
For real-world teams, the best frame is not endoscopy versus IR. It is anatomy-guided and physiology-guided step-up care.
Device choice is more nuanced than “AXIOS protocol”
LAMS changed what endoscopic drainage can do, especially for necrotic collections that may need repeat access or direct endoscopic necrosectomy. AGA’s best practice advice still supports large-bore self-expanding metal stents, including LAMS, over plastic stents for endoscopic drainage of necrosis.
That is different from saying every drained collection requires a LAMS. The more useful 2026 question is what the cavity contains and what the next step is likely to be. If the collection is necrotic and repeat access may matter, LAMS are attractive. If the issue is simpler fluid drainage, the device conversation is less ideological.
One newer nuance is the growing use of coaxial double-pigtail plastic stents through a LAMS. A 2025 meta-analysis found lower overall adverse events and lower infection rates with LAMS plus coaxial plastic stents than with LAMS alone, without a difference in clinical success. That does not settle every case, but it is a practical detail worth remembering.
A practical access-route table for daily use
| Access route | Best fit | Main limitation |
|---|---|---|
| EUS-guided transmural drainage | Symptomatic or infected pseudocyst or WON that is luminally accessible in an expert center | Requires anatomy that actually fits the approach and a team that can manage complications |
| Percutaneous drainage | Early infected collections, unstable patients, or deep extensions beyond a good transluminal route | External drains, patient burden, and pancreatocutaneous fistula risk |
| Direct endoscopic necrosectomy | Persistent necrotic cavity after drainage or large infected debris burden | Should not be the first reflex and needs referral-center backup |
What not to do in 2026
- Do not drain an asymptomatic collection purely because the report mentions size.
- Do not treat “4 weeks” like an inflexible ritual while ignoring clinical deterioration or anatomy that favors IR.
- Do not talk about PFC drainage as if the only serious device question is whether to place a LAMS.
- Do not start direct endoscopic necrosectomy as a reflex when drainage alone has not yet had a chance to work.
Selected references
- American Gastroenterological Association Clinical Practice Update: Management of Pancreatic Necrosis. Gastroenterology. 2020.
- ACG Guideline Highlights: Management of Acute Pancreatitis. 2024.
- Early versus delayed catheter drainage for patients with necrotizing pancreatitis and early persistent organ failure (TIMING). Intensive Care Med. 2025.
- EUS-guided Drainage of Pancreatic Fluid Collections Using Lumen Apposing Metal Stents With or Without Coaxial Plastic Stents. J Clin Gastroenterol. 2025.
Last reviewed April 17, 2026. This update is written for clinicians deciding when endoscopic drainage is appropriate, when waiting is safer, and when percutaneous access still belongs in the first-line plan.
